

Appendix H
2006 Cardiovascular Biomarkers and Surrogate Endpoints Symposium Faculty

Michelle A. Albert	Harvard Medical School
Pierre Amarenco	Claude Bernard University Hospital
Lawrence J. Appel	Johns Hopkins Medical Institutions
Robert S. Balaban	National Heart, Lung and Blood Institute
Eric P. Brass	Harbor-UCLA Medical Center
H. Bryan Brewer	Cardiovascular Research Institute
James De Lemos	University of Texas-Southwestern Medical School
Zahi A. Fayad	Mount Sinai School of Medicine
Bruce Furie	Harvard Medical School
Robert Gerszten	Massachusetts General Hospital
Federico Goodsaid	Office of Clinical Pharmacology, FDA
Philip Greenland	Feinberg School of Medicine-Northwestern University
Steven M. Haffner	University of Texas Health Centers
Robert A. Harrington	Duke University Medical Center
Jay W. Heinecke	University of Washington
Therese Heinonen	Montreal Heart Institute
Allan S. Jaffe	Mayo Clinic College of Medicine
Timao Li	Health Canada
Ronald M. Krauss	University of California
Philippe L'Allier	Montreal Heart Institute
Joao Lima	Johns Hopkins Medical School
Jonathan R. Lindner	Oregon Health & Science University
Douglas L. Mann	Baylor Heart Clinic, Baylor College of Medicine
Clemens Mittmann	Federal Institute for Drugs and Medical Devices (BfArM)
David A. Morrow	Brigham and Women's Hospital
Christopher O'Donnell	NHLBI National Institutes of Health
David G. Orloff, M.D	Medpace, Inc.
Mary Parks	Division of Metabolism and Endocrine Products, FDA
Margaret Prescott	Novartis Institute for Biomedical Research
Gurvaneet Randhaw	Center for Outcomes and Evidence, HHS, AHRQ
Paul M. Ridker	Brigham and Women's Hospital
Eric Rimm	Harvard School of Public Health
Frank Sack	Harvard School of Public Health
Norman Stockbridge	Division of Cardio-Renal Drug Products, FDA
Allen Taylor	Walter Reed Army Medical Center
Douglas C. Throckmorton	Director, Center for Drug Evaluation and Research, FDA
Paula R. Trumbo	Center for Food Safety and Applied Nutrition, FDA